Renhua Li

发表

In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist

Jodi L. Smith, P. Ornstein, Xia Li, 2017, Neuropharmacology.

Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.

J. F. Soriano, P. Ornstein, M. Blanco, 2016, Bioorganic & medicinal chemistry letters.

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.

P. Lam, K. He, R. Knabb, 2006, Bioorganic & medicinal chemistry letters.

Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.

P. Lam, R. Knabb, R. Alexander, 2005, Journal of medicinal chemistry.

Copper promoted CN and CO bond cross-coupling with phenyl and pyridylboronates

P. Lam, Renhua Li, D. Bonne, 2003 .

Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.

Xiaobing Wang, L. Kong, Renhua Li, 2013, Bioorganic & medicinal chemistry letters.

Copper-Promoted C−N Bond Cross-Coupling with Hypervalent Aryl Siloxanes and Room-Temperature N-Arylation with Aryl Iodide

P. Lam, Mingyang He, Renhua Li, 2000 .

Metabotropic Glutamate Receptor

J. F. Soriano, P. Ornstein, S. Atwell, 2016 .

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.

P. Lam, K. He, R. Knabb, 2003, Journal of medicinal chemistry.

Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.

J. F. Soriano, P. Ornstein, S. Atwell, 2016, Journal of medicinal chemistry.

Copper-Promoted C—N and C—O Bond Cross-Coupling with Phenyl and Pyridylboronates.

P. Lam, Renhua Li, D. Bonne, 2003 .

Highly fluorescent CsPbBr3/TiO2 core/shell perovskite nanocrystals with excellent stability

Renhua Li, Haitao Chen, Yu Xia, 2021, SN Applied Sciences.

Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension

Q. Guo, Renhua Li, Yue Yang, 2020, Annals of translational medicine.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

P. Ornstein, S. Mitchell, G. Gilmour, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects

D. McKinzie, G. Gilmour, J. Witkin, 2017, Pharmacology Biochemistry and Behavior.